Summary of Study ST000526

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000387. The data can be accessed directly via it's Project DOI: 10.21228/M81G7P This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000526
Study TitleEffects of Curcumin Supplementation on the Ceramides Concentration of Older Adults: Relation to Vascular Function (part 3)
Study SummaryPerform ceramides concentrations metabolite analysis related to nitric oxide biology, oxidative stress and inflammation in plasma before and after 12 weeks of oral curcumin (2000 mg/d) or placebo (double-blind, randomized) in men and women aged 45-79 years who are free from clinical cardiovascular disease.
Institute
Mayo Clinic
Last NameSeals
First NameDouglas
AddressDepartment of Integrative Physiology University of Colorado Boulder, CO 80309
Emailseals@colorado.edu
Phone303-492-5305
Submit Date2016-12-14
Analysis Type DetailLC-MS
Release Date2018-12-11
Release Version1
Douglas Seals Douglas Seals
https://dx.doi.org/10.21228/M81G7P
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000387
Project DOI:doi: 10.21228/M81G7P
Project Title:Mayo Metabolomics Pilot and Feasibility Award: Effects of Curcumin Supplementation on the Plasma Metabolome of Older Adults: Relation to Vascular Function
Project Summary:Age is the major risk factor for cardiovascular diseases (CVD). Two key contributors to the increased risk of CVD in middle-aged and older (MA/O) adults are stiffening of the large elastic arteries and the development of vascular endothelial dysfunction, indicated by impaired nitric oxide (NO)-induced endothelium-dependent dilation (EDD). The mechanisms by which aging causes arterial dysfunction are incompletely understood, but involve reductions in NO bioavailability associated with the development of oxidative stress and inflammation. Thus, establishing novel strategies to reduce arterial stiffness and increase vascular endothelial function in MA/O adults by increasing NO bioavailability and reducing oxidative stress and inflammation are a high biomedical research priority. Curcumin is a naturally occurring phenol found in the Indian spice turmeric that improves physiological function in animal models of age-related diseases and is a promising nutraceutical for intervention for promoting healthy aging. Our preclinical results indicate that chow supplemented with curcumin reduces aortic pulse wave velocity (PWV), the most common and clinically important measure of large elastic artery stiffness, restores NO-mediated EDD and reduces arterial oxidative stress and inflammation in old C57/BL6 mice. Preliminary data from our recently funded NIH R21 pilot grant indicate that curcumin supplementation improves vascular function in humans. It is possible that changes in the circulating (plasma) metabolome with oral curcumin supplementation will provide insight into novel metabolic mechanisms by which curcumin may improve vascular function. The goal of this project is to identify key metabolic pathways that change with oral curcumin supplementation and to relate those changes with improvements in vascular function in MA/O adults with initial endothelial dysfunction. Metabolomic analysis of plasma samples at baseline also may produce unique molecular signatures that predict responsiveness (changes in vascular function) to curcumin supplementation among individuals.
Institute:Mayo Clinic
Last Name:Seals
First Name:Douglas
Address:Department of Integrative Physiology University of Colorado Boulder, CO 80309
Email:seals@colorado.edu
Phone:303-492-5305

Subject:

Subject ID:SU000548
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id group Time point
SA027611ms5533-29Old-Curcumin Post
SA027612ms5588-15Old-Curcumin Post
SA027613ms5588-22Old-Curcumin Post
SA027614ms5533-15Old-Curcumin Post
SA027615ms5533-18Old-Curcumin Post
SA027616ms5533-27Old-Curcumin Post
SA027617ms5533-20Old-Curcumin Post
SA027618ms5533-22Old-Curcumin Post
SA027619ms5588-27Old-Curcumin Post
SA027620ms5588-29Old-Curcumin Post
SA027621ms5533-3Old-Curcumin Post
SA027622ms5588-3Old-Curcumin Post
SA027623ms5588-25Old-Curcumin Post
SA027624ms5588-5Old-Curcumin Post
SA027625ms5533-10Old-Curcumin Post
SA027626ms5533-8Old-Curcumin Post
SA027627ms5533-26Old-Curcumin Pre
SA027628ms5588-14Old-Curcumin Pre
SA027629ms5588-4Old-Curcumin Pre
SA027630ms5533-28Old-Curcumin Pre
SA027631ms5533-19Old-Curcumin Pre
SA027632ms5533-9Old-Curcumin Pre
SA027633ms5588-24Old-Curcumin Pre
SA027634ms5533-7Old-Curcumin Pre
SA027635ms5588-26Old-Curcumin Pre
SA027636ms5533-2Old-Curcumin Pre
SA027637ms5533-14Old-Curcumin Pre
SA027638ms5588-28Old-Curcumin Pre
SA027639ms5533-21Old-Curcumin Pre
SA027640ms5588-2Old-Curcumin Pre
SA027641ms5533-17Old-Curcumin Pre
SA027642ms5588-21Old-Curcumin Pre
SA027643ms5588-18Old-Placebo Post
SA027644ms5588-10Old-Placebo Post
SA027645ms5588-13Old-Placebo Post
SA027646ms5588-20Old-Placebo Post
SA027647ms5588-8Old-Placebo Post
SA027648ms5533-32Old-Placebo Post
SA027649ms5533-34Old-Placebo Post
SA027650ms5588-32Old-Placebo Post
SA027651ms5588-34Old-Placebo Post
SA027652ms5533-25Old-Placebo Post
SA027653ms5533-13Old-Placebo Post
SA027654ms5588-36Old-Placebo Post
SA027655ms5533-5Old-Placebo Post
SA027656ms5533-36Old-Placebo Post
SA027657ms5533-4Old-Placebo Pre
SA027658ms5533-24Old-Placebo Pre
SA027659ms5588-19Old-Placebo Pre
SA027660ms5533-12Old-Placebo Pre
SA027661ms5588-35Old-Placebo Pre
SA027662ms5588-17Old-Placebo Pre
SA027663ms5533-31Old-Placebo Pre
SA027664ms5588-7Old-Placebo Pre
SA027665ms5588-31Old-Placebo Pre
SA027666ms5588-33Old-Placebo Pre
SA027667ms5533-33Old-Placebo Pre
SA027668ms5533-35Old-Placebo Pre
SA027669ms5588-9Old-Placebo Pre
SA027670ms5588-12Old-Placebo Pre
SA027671ms5588-37young Baseline
SA027672ms5588-30young Baseline
SA027673ms5588-1young Baseline
SA027674ms5533-23young Baseline
SA027675ms5533-16young Baseline
SA027676ms5533-11young Baseline
SA027677ms5533-6young Baseline
SA027678ms5533-30young Baseline
SA027679ms5533-37young Baseline
SA027680ms5588-16young Baseline
SA027681ms5588-11young Baseline
SA027682ms5588-6young Baseline
SA027683ms5533-1young Baseline
SA027684ms5588-23young Baseline
Showing results 1 to 74 of 74

Collection:

Collection ID:CO000542
Collection Summary:Healthy men & women aged 45-79 without clinical CVD, but with below normal baseline endothelial dysfunction (FMDBA < 7%).
Sample Type:Blood

Treatment:

Treatment ID:TR000562
Treatment Summary:A 12-week randomized, double-blind, placebo controlled study will be conducted. After CTRC screening for inclusion/exclusion criteria, qualified subjects will be randomly assigned to 1 of 2 groups. The investigators involved in the acquisition and analysis of key outcomes will be blinded to the curcumin intake status of the subjects. With the assistance of dietary monitoring from the UC-Boulder CTRC bionutritionists, subjects will maintain their baseline diet with either unchanged (control) or enhanced curcumin intake delivered as capsules (Longvida®, Verdure Sciences): Group 1 = placebo (inert substances); Group 2 = curcumin (2000mg curcumin/day). Extensive published work has established that the curcumin dose of 2000 mg/day is well tolerated and safe. Sessions 1 & 2: Screening measurements. Session 3: Baseline measurements and blood draw. Sessions 4-8 (every other week to assess adherence and overall subject well-being): Body weight, BP, adherence, discuss any problems. Session 9: Identical to session 3 (stop intake of capsules after completion of post-testing).

Sample Preparation:

Sampleprep ID:SP000555
Sampleprep Summary:Venous blood sampling. All blood samples are handled in a similar time frame and immediately spun to extract plasma and stored in our -80 freezer until ready for analysis. Ceramides concentrations in plasma.

Combined analysis:

Analysis ID AN000804
Analysis type MS
Chromatography type HILIC
Chromatography system Waters Acquity
Column AMT HALO HILIC 2 (150 x 4.6mm,2.7um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Thermo Quantiva QQQ
Ion Mode POSITIVE
Units uM

Chromatography:

Chromatography ID:CH000579
Instrument Name:Waters Acquity
Column Name:AMT HALO HILIC 2 (150 x 4.6mm,2.7um)
Chromatography Type:HILIC

MS:

MS ID:MS000711
Analysis ID:AN000804
Instrument Name:Thermo Quantiva QQQ
Instrument Type:Triple quadrupole
MS Type:ESI
Ion Mode:POSITIVE
  logo